Patent intelligence · US
US 12325699
Antibacterial compounds
Antibacterial compounds
Patent details — US 12325699
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 10, 2025
- Expiration
- Jun 5, 2045
- Applicant
- BLACKSMITH MEDICINES, INC.
- Claims
- 18
- CPC classes
- A61P, A61P13/02, A61P31/04
Quick answer
US 12325699 (Antibacterial compounds) is held by BLACKSMITH MEDICINES, INC.. Status: granted. Granted Jun 10, 2025. Expires Jun 5, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BLACKSMITH MEDICINES, INC.
- Grant date
- Expiration
- Claims
- 18
- CPC classes
- A61P, A61P13/02, A61P31/04
More from BLACKSMITH MEDICINES, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12343394
CD38 modulating antibody agents
granted -
US 12304964
CD38 modulating antibody
granted -
US 12187754
LpxC inhibitors and uses thereof
granted -
US 12161717
CD38 modulating antibody agents
granted -
US 12162949
CD38 antibody
granted -
US 11897873
Kappa opioid receptor antagonists and products and methods related thereto
granted -
US 11780930
CD38 modulating antibody
granted
Frequently asked questions
What is US patent 12325699?
US 12325699 (Antibacterial compounds) is held by BLACKSMITH MEDICINES, INC.. Status: granted. Granted Jun 10, 2025. Expires Jun 5, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12325699?
BLACKSMITH MEDICINES, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 38 pharmaceutical patents for this assignee.
When does US 12325699 expire?
Our index shows an expiration date of Jun 5, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.